RMD

ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2005

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation, for the period ended March 31, 2005. ResMed designs, manufactures, and markets devices for the evaluation and treatment of sleep-disordered breathing, primarily obstructive sleep apnea. Manufacturing operations are located in Australia, Germany, and the United States, with major distribution sites globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 19% for the quarter and 22% for the nine-month period compared to the prior year. Growth was driven by increased unit sales of flow generators and masks, as well as favorable currency translation effects ($1.9 million and $8.7 million for the three and nine-month periods, respectively).
• Profitability: Gross profit margins improved to 65% for both periods (up from 63% and 64% in the prior year) due to a favorable product mix with higher-margin mask sales.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 22% (quarter) and 24% (nine months), primarily due to increased personnel and currency impacts. Restructuring expenses of $1.6 million (quarter) and $4.5 million (nine months) were incurred related to the integration of German operations.
• Balance Sheet: Inventories increased 31% to $75.5 million to support production volumes and new product launches. Accounts receivable increased 35% to $89.1 million, with days outstanding rising to 70 days (from 64 days) due to processing delays in Germany.

Outlook, Risks, and Unusual Items

• Acquisitions: The company acquired Hoefner Medizintechnick GmbH (Germany) in February 2005 for net cash of $8.1 million and Resprecare BV (Netherlands) in December 2004 for $5.8 million. A subsequent event disclosed an agreement to acquire Saime SA (France/Germany) for approximately $112 million, expected to close in May 2005.
• Restructuring: Total restructuring costs for the integration of ResMed Germany and MAP are estimated at $5.0 million, with most expenses expected to be incurred in the remainder of fiscal 2005.
• Capital Expenditures: Significant spending ($26.2 million for the nine months) is directed toward the construction of a new sleep center and R&D facilities in Sydney, Australia. Total estimated costs for these facilities are approximately $52 million.
• Debt Maturity: $113.3 million in 4% convertible subordinated notes mature on June 20, 2006. The company noted it may not have sufficient funds to repay these notes if they are not converted, though it has no current credit facilities specifically for this purpose.
• Accounting Changes: The company expects to adopt SFAS 123(R) regarding share-based payments in the fiscal year beginning July 1, 2005, which may significantly impact reported net income.

Investor Verification Checklist

• Debt Repayment Strategy: Verify the company's specific plan to repay or refinance the $113.3 million convertible notes maturing in June 2006, given the lack of dedicated credit facilities mentioned.
• German Operations Integration: Monitor the resolution of sales processing delays in Germany and the impact on accounts receivable days outstanding (currently 70 days).
• Acquisition Financing: Confirm the funding sources for the pending $112 million acquisition of Saime SA and its impact on liquidity.
• Inventory Levels: Assess whether the 31% increase in inventory aligns with sales velocity to avoid potential obsolescence or write-downs.
• Stock-Based Compensation Impact: Review the pro forma impact of the upcoming adoption of SFAS 123(R) on future earnings per share.